SeaStar Medical Provides Updates On Enrollment Of Adult Pivotal Clinical Study And Commercial Launch Of Quelimmune, FDA-Approved In Pediatric Patients
SeaStar Medical Provides Updates On Enrollment Of Adult Pivotal Clinical Study And Commercial Launch Of Quelimmune, FDA-Approved In Pediatric Patients
SeaStar Medical提供成人關鍵臨床研究註冊的最新情況，以及獲得美國食品藥品管理局批准的針對兒科患者的Quelimmune的商業發佈
Company plans to hold a business update conference call in April
公司計劃在四月份舉行業務更新電話會議
DENVER, March 12, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, provides updates on the acute kidney injury (AKI) programs it is developing with its patented, first-to-market, cell-directed Selective Cytopheretic Device (SCD) extracorporeal therapy in critically ill patients with AKI.
丹佛，2024年3月12日（GLOBE NEWSWIRE）——SeaStar Medical Holding Corporation（納斯達克股票代碼：ICU）是一家開發專有解決方案以減少重要器官過度炎症影響的商業階段醫療器械公司（納斯達克股票代碼：ICU），該公司提供了其正在開發的針對AKI危重患者的急性腎損傷（AKI）項目的最新情況。
"We now have 21 subjects enrolled across five clinical sites in our NEUTRALIZE-AKI pivotal clinical trial, which is intended to evaluate the safety and efficacy of our SCD in...
“現在，我們的NEUTRALIZE-AKI關鍵臨床試驗在五...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間